Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage gene editing company focused on developing in vivo therapies for serious diseases with limited treatment options. Its proprietary ARCUS® genome editing platform is designed to make precise changes to DNA and supports programs aimed at treating chronic hepatitis B, Duchenne muscular dystrophy, and other high-unmet-need conditions. The company’s current work centers on advancing therapeutic candidates through clinical development, with an emphasis on direct gene correction, elimination, or insertion in targeted tissues. Precision BioSciences serves the biotechnology and life sciences markets by applying its editing technology to human therapeutics, positioning itself as a specialist in next-generation genetic medicine from its headquarters in Durham, North Carolina.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Michael Amoroso

Employees

67

Headquarters

Durham, NC, United States

Website

precisionbiosciences.com